

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2003. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/736051-Conf. #8748		
		Filing Date	December 13, 2000		
		First Named Inventor	Hua Z. Ke		
		Art Unit	1654		
		Examiner Name	L. N. Leary		
Sheet	1	of	1	Attorney Docket Number	PC9344BRTR (121*254)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
LL	CA	Lax et al., Antagonistic Action of Estrogens, Flutamide, and Human Growth Hormone on Androgen-Induced Changes in the Activities of Some Enzymes of Hepatic Steroid Metabolism in the Rat. Endocrinology 113(3):1043-1055 (1983).			
LL	CB	Wronski et al., Parathyroid Hormone Is More Effective than Estrogen or Bisphosphonates for Restoration of Lost Bone Mass in Ovariectomized Rats. Endocrinology 132(2):823-831 (1993).			
LL	CC	Evans et al., The Effects of Raloxifene on Tibia Histomorphometry in Ovariectomized Rats. Endocrinology 134(5):2283-2288 (1994).			
LL	CD	Budavari et al., eds., The Merck Index, 12th Edition, entry for #8864 Somatotropin. Whitehouse Station, NJ: Merck Research Laboratories, 1996, pp. 1488-1489.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 327160_120C		Date Considered	7/04
-----------------------------------	---	-----------------	------